MX363050B - Composición inmunogénica para modulación del sistema inmune y su uso, metodo de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune. - Google Patents
Composición inmunogénica para modulación del sistema inmune y su uso, metodo de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune.Info
- Publication number
- MX363050B MX363050B MX2013010669A MX2013010669A MX363050B MX 363050 B MX363050 B MX 363050B MX 2013010669 A MX2013010669 A MX 2013010669A MX 2013010669 A MX2013010669 A MX 2013010669A MX 363050 B MX363050 B MX 363050B
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- present
- treating
- immune response
- immune
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000028993 immune response Effects 0.000 title abstract 2
- 210000000987 immune system Anatomy 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 230000008929 regeneration Effects 0.000 title abstract 2
- 238000011069 regeneration method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 210000000750 endocrine system Anatomy 0.000 abstract 1
- 230000002008 hemorrhagic effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 201000004193 respiratory failure Diseases 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
Abstract
La presente invención se refiere a composiciones inmunogénicas para la modulación del sistema inmune que comprende una cantidad terapéuticamente efectiva de dos o más agentes antigénicos imunoactivos que presentan patrones moleculares asociados a patógenos (PAMPS) y / o patrones moleculares asociados a peligro (DAMPS) y o más de un vehículo, excipiente o diluyente fisiológicamente aceptable. Las composiciones inmunogénicas de la presente invención se utilizan en la fabricación de medicamentos para la prevención y / o tratamiento y en la prevención y / o tratamiento de enfermedades infecciosas, enfermedades autoinmunes, enfermedades alérgicas, inflamación, artritis, enfermedades inflamatorias, rechazo de trasplantes, enfermedades causadas por los trastornos vasculares, enfermedades causadas por eventos cardiovasculares hemorrágicos o isquémica, isquemia, infarto y hemorragia que conduce a destrucción del tejido cardiaca, renal, respiratoria o enfermedad de hígado, cáncer, tumores y lesiones benignas y malignas. La presente invención se refiere además a métodos para inducir la regeneración celular, la regeneración de tejidos, la regeneración de órganos y la regeneración de los sistemas orgánicos, tales como el sistema circulatorio, sistema nervioso y sistema endocrino. Por último, la presente invención se refiere a métodos para la renovación de la respuesta inmune en u animal, particularmente seres humanos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI1100857-1A BRPI1100857A2 (pt) | 2011-03-18 | 2011-03-18 | agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real |
PCT/BR2012/000072 WO2012122618A1 (pt) | 2011-03-17 | 2012-03-19 | Composição imunogênica para modulação do sistema imune e seu uso, método de tratamento e prevenção de doenças, método para induzir a regeneração celular e método para recondução da resposta imune |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013010669A MX2013010669A (es) | 2014-10-14 |
MX363050B true MX363050B (es) | 2019-03-06 |
Family
ID=46829971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013010669A MX363050B (es) | 2011-03-18 | 2012-03-19 | Composición inmunogénica para modulación del sistema inmune y su uso, metodo de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune. |
Country Status (16)
Country | Link |
---|---|
US (1) | US9566330B2 (es) |
EP (1) | EP2687227B1 (es) |
JP (2) | JP6181636B2 (es) |
KR (1) | KR102008535B1 (es) |
CN (1) | CN103717233B (es) |
AU (1) | AU2012229902B2 (es) |
BR (2) | BRPI1100857A2 (es) |
CA (1) | CA2837348A1 (es) |
CL (1) | CL2013002712A1 (es) |
CO (1) | CO6831973A2 (es) |
DK (1) | DK2687227T3 (es) |
ES (1) | ES2699264T3 (es) |
MX (1) | MX363050B (es) |
PT (1) | PT2687227T (es) |
RU (1) | RU2678317C2 (es) |
WO (1) | WO2012122618A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10213504B2 (en) | 2011-03-18 | 2019-02-26 | Alexandre Eduardo Nowill | Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
SG11201510150VA (en) | 2013-06-21 | 2016-01-28 | Ondek Pty Ltd | Immunotherapy composition and use thereof |
PE20170298A1 (es) | 2014-03-28 | 2017-04-18 | Opko Diagnostics Llc | Composiciones y metodos relacionados con el diagnostico del cancer de prostata |
KR101631312B1 (ko) * | 2014-06-16 | 2016-06-20 | 연세대학교 산학협력단 | 재조합 람블편모충 결합 면역글로블린 단백질을 포함하는 면역증강 조성물 |
CN104546937B (zh) * | 2014-09-30 | 2019-02-01 | 深圳华大基因科技有限公司 | 系结梭菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
HUE037476T2 (hu) | 2014-12-23 | 2018-08-28 | 4D Pharma Res Ltd | Pirin polipeptid és immunmodulálás |
LT3065748T (lt) | 2014-12-23 | 2018-03-12 | 4D Pharma Research Limited | Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui |
PT3253800T (pt) | 2015-03-27 | 2021-04-28 | Opko Diagnostics Llc | Padrões de antigénio da próstata e suas utilizações |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
RS59308B1 (sr) | 2015-06-15 | 2019-10-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
EP3636272A1 (en) | 2015-06-15 | 2020-04-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
LT3650033T (lt) | 2015-06-15 | 2022-04-11 | 4D Pharma Research Limited | Kompozicijos, apimančios bakterinius kamienus |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB2561748B (en) | 2015-11-20 | 2019-05-08 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
TW201733601A (zh) | 2016-03-04 | 2017-10-01 | 4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
IL268626B2 (en) * | 2017-02-13 | 2024-04-01 | Alexandre Eduardo Nowill | Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient |
MA48940A (fr) | 2017-05-22 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
MD3638271T2 (ro) | 2017-06-14 | 2021-03-31 | 4D Pharma Res Ltd | Compoziții cuprizând tulpini bacteriene |
DK3804737T3 (da) | 2017-06-14 | 2022-07-25 | 4D Pharma Res Ltd | Sammensætninger omfattende bakteriestammer |
RU2699540C2 (ru) * | 2017-08-17 | 2019-09-06 | Павел Павлович Несмиянов | Композиция, содержащая пробиотические бактерии или их компоненты, и способ ее применения в лечении иммунных заболеваний кожи |
AU2019215191A1 (en) * | 2018-02-02 | 2020-09-17 | University Of Washington | Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling |
CN109010824A (zh) * | 2018-08-27 | 2018-12-18 | 广州汇高生物科技有限公司 | 一种特异性卵黄免疫球蛋白组合物及其制剂 |
WO2020106158A1 (en) * | 2018-11-20 | 2020-05-28 | Acd Pharmaceuticals As | Serratia liquefaciens variant |
ES2962407T3 (es) * | 2018-12-04 | 2024-03-18 | Sabiotec Spin Off S L | Inmunoestimulante para su uso contra patógenos |
CN110156885B (zh) * | 2019-05-23 | 2020-11-24 | 南京林业大学 | 松材线虫的病原相关模式分子蛋白BxCDP1及其应用 |
WO2022040768A1 (en) * | 2020-08-28 | 2022-03-03 | Nowill Alexandre Eduardo | Compositions for uses in methods of treating coronavirus infections |
CN113244273A (zh) * | 2021-03-16 | 2021-08-13 | 广州中科蓝华生物科技有限公司 | 疟原虫在制备联合放射疗法用于抗肿瘤的制剂中的应用 |
CN114606317B (zh) * | 2022-03-22 | 2022-12-02 | 中山大学附属第一医院 | 一种预测胃癌***转移的菌群标志物及其应用 |
DE202023103094U1 (de) | 2023-06-06 | 2023-06-30 | Dasari Chandransh | Ein System zur Regeneration menschlicher Zellen mit isoliertem regenerativem Gen eines Planarienorganismus |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
SI1659178T1 (sl) * | 1998-02-05 | 2010-07-30 | Glaxosmithkline Biolog Sa | Postopek za čiščenje ali proizvodnjo MAGE proteina |
US6432710B1 (en) * | 1998-05-22 | 2002-08-13 | Isolagen Technologies, Inc. | Compositions for regenerating tissue that has deteriorated, and methods for using such compositions |
AT410635B (de) * | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
WO2004096270A1 (en) * | 2003-04-30 | 2004-11-11 | Medi Service S.R.L. | Immunomodulating composition comprising a particulate fraction of bacterial mechanical lysates |
WO2005077408A2 (en) * | 2004-02-06 | 2005-08-25 | Vaxinnate Corporation | Compositions of pamps and listeria monocytogenes and methods of use |
PL1765391T3 (pl) * | 2004-06-07 | 2013-08-30 | Qu Biologics Inc | Kompozycje bakteryjne do leczenia nowotworów |
EP1807446A2 (en) * | 2004-10-08 | 2007-07-18 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic and therapeutic compositions for streptococcus pyogenes |
US20100047266A1 (en) * | 2006-07-27 | 2010-02-25 | Ligocyte Pharmaceuticals, Inc. | Chimeric virus-like particles |
EP2977456B1 (en) * | 2006-08-15 | 2017-10-25 | The Trustees Of The University Of Pennsylvania | Compositions comprising hmw-maa and fragments thereof for treating cancer |
EP1938835A1 (en) * | 2006-12-29 | 2008-07-02 | Pevion Biotech AG | Non-specific immunostimulating agents |
WO2009073133A1 (en) * | 2007-11-29 | 2009-06-11 | Vaxinnate Corporation | Compositions of toll-like receptor agonists and papillomavirus antigens and uses thereof |
EP2303236A4 (en) * | 2008-07-01 | 2012-09-26 | Univ Emory | SYNERGISTIC INDUCTION OF HUMOR AND CELLULAR IMMUNITY BY COMBINATORY ACTIVATION OF TOLL-LIKE RECEPTORS |
WO2010037402A1 (en) * | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US20120093855A1 (en) * | 2008-11-18 | 2012-04-19 | Ligocyte Pharmaceuticals, Inc. | RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF |
-
2011
- 2011-03-18 BR BRPI1100857-1A patent/BRPI1100857A2/pt not_active Application Discontinuation
-
2012
- 2012-03-19 EP EP12757249.3A patent/EP2687227B1/en active Active
- 2012-03-19 ES ES12757249T patent/ES2699264T3/es active Active
- 2012-03-19 DK DK12757249.3T patent/DK2687227T3/en active
- 2012-03-19 WO PCT/BR2012/000072 patent/WO2012122618A1/pt active Application Filing
- 2012-03-19 PT PT12757249T patent/PT2687227T/pt unknown
- 2012-03-19 AU AU2012229902A patent/AU2012229902B2/en active Active
- 2012-03-19 RU RU2013143400A patent/RU2678317C2/ru active
- 2012-03-19 JP JP2014500207A patent/JP6181636B2/ja active Active
- 2012-03-19 CA CA2837348A patent/CA2837348A1/en not_active Abandoned
- 2012-03-19 MX MX2013010669A patent/MX363050B/es unknown
- 2012-03-19 KR KR1020137027403A patent/KR102008535B1/ko active IP Right Grant
- 2012-03-19 CN CN201280024132.7A patent/CN103717233B/zh active Active
- 2012-03-19 BR BR112013023773A patent/BR112013023773B8/pt active IP Right Grant
- 2012-03-19 US US14/006,077 patent/US9566330B2/en active Active
-
2013
- 2013-09-23 CL CL2013002712A patent/CL2013002712A1/es unknown
- 2013-10-17 CO CO13246905A patent/CO6831973A2/es unknown
-
2017
- 2017-02-24 JP JP2017033884A patent/JP2017132776A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2687227A4 (en) | 2014-10-01 |
JP2014508783A (ja) | 2014-04-10 |
RU2013143400A (ru) | 2015-04-27 |
KR102008535B1 (ko) | 2019-10-21 |
ES2699264T3 (es) | 2019-02-08 |
US20140037716A1 (en) | 2014-02-06 |
BR112013023773B8 (pt) | 2022-10-18 |
WO2012122618A8 (pt) | 2012-11-08 |
EP2687227A1 (en) | 2014-01-22 |
BRPI1100857A2 (pt) | 2013-05-21 |
AU2012229902A1 (en) | 2013-11-07 |
MX2013010669A (es) | 2014-10-14 |
CN103717233B (zh) | 2020-05-26 |
CA2837348A1 (en) | 2012-09-20 |
JP2017132776A (ja) | 2017-08-03 |
RU2678317C2 (ru) | 2019-01-28 |
PT2687227T (pt) | 2018-12-11 |
BR112013023773B1 (pt) | 2022-09-20 |
WO2012122618A1 (pt) | 2012-09-20 |
DK2687227T3 (en) | 2018-12-10 |
CN103717233A (zh) | 2014-04-09 |
CL2013002712A1 (es) | 2014-08-18 |
NZ616823A (en) | 2016-08-26 |
JP6181636B2 (ja) | 2017-08-16 |
EP2687227B1 (en) | 2018-08-22 |
BR112013023773A2 (pt) | 2020-11-10 |
US9566330B2 (en) | 2017-02-14 |
CO6831973A2 (es) | 2014-01-10 |
KR20140027162A (ko) | 2014-03-06 |
AU2012229902B2 (en) | 2017-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX363050B (es) | Composición inmunogénica para modulación del sistema inmune y su uso, metodo de tratamiento y prevención de enfermedades, método para inducir la regeneración celular y procedimiento para la reconducción de la respuesta inmune. | |
EP4140487A8 (en) | Combination therapy for treating cancer | |
EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
WO2012071526A3 (en) | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
EA201101145A1 (ru) | Фармацевтические композиции, которые содержат имидазохинолин(амины) и их производные, пригодные для местного введения | |
BR112014027971A2 (pt) | dispositivos médicos revestidos incluindo um agente terapêutico insolúvel em água | |
WO2012125926A3 (en) | Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases | |
MX362098B (es) | El uso de células derivadas de tejido del cordón umbilical y kits que contienen las mismas para el tratamiento de enfermedad vascular periférica. | |
MX2013013560A (es) | Tratamiento de la degeneracion del disco intervertebral mediante el uso de celulas humanas derivadas de tejido del cordon umbilical. | |
IN2015DN02938A (es) | ||
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
WO2012106551A1 (en) | Bakuchiol compositions for treatment of post inflammatory hyperpigmentation | |
MX2014000567A (es) | Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios. | |
WO2014183033A3 (en) | G-csf for use in treating or preventing a disease associated with aging in a patient, for administration with a stem-cell containing composition and/or an electromagnetic signal | |
AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
ECSP14013157A (es) | Formulaciones liofilizadas de fgf-18 | |
AR092736A1 (es) | Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r | |
BR112022003659A2 (pt) | Composições e métodos de tratamento de doenças vasculares | |
BR112013032911A2 (pt) | leucotoxina e/d como um novo agente anti-inflamatório e microbicida | |
AU2012388759A8 (en) | Methods and compositions for hypotensive resuscitation | |
MX350719B (es) | Composiciones de bakuchiol para el tratamiento de hiperpigmentacion post-inflamatoria. | |
EA201390925A1 (ru) | Производные санглиферина и способы их получения | |
WO2014140930A3 (en) | Compostions and methods for enhancing the therapeutic potential of stem cells |